News Sentiment

BRNS sentiment intelligence

Barinthus Biotherapeutics plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.56 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-12.9% over one week, -16.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Barinthus Biotherapeutics (NasdaqCM:BRNS) Stock Price

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -12.9% Price reacting lower
Trend fit Trend inactive -16.1% over four weeks
Fair value -63.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 31
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
TradingKey 8
Market source 7
Stock Titan 6
dars.gov.et 3
simplywall.st 2
MarketBeat 2
Simply Wall Street 1

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 16
Deals and strategy 3
Analyst action 2
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
Simply Wall Street Direct company coverage

Barinthus Biotherapeutics (NasdaqCM:BRNS) Stock Price

Barinthus Biotherapeutics (NasdaqCM:BRNS) has a market cap of US$26.1m and its stock price recently decreased by 36.22% over seven days. The company, founded in 2016, focuses on immunotherapies and vaccines, with candidates in clinical trials for celiac disease and chronic hepati

Tone
Negative 39/100
Event
Market update
Published
05 Jul 2026 01:10
Source
Simply Wall Street
Stock Titan Direct company coverage

Barinthus Biotherapeutics (BRNS) wins more time to meet Nasdaq $1 bid rule

Barinthus Biotherapeutics (BRNS) has been granted an additional 180 days, until December 28, 2026, by Nasdaq to regain compliance with the minimum $1.00 per share bid price requirement. In connection with this extension, its American Depositary Shares were transferred from the Na

Tone
Negative 29/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Barinthus Biotherapeutics plc – NASDAQ:BRNS

This article provides the "Price to book forward" value for Barinthus Biotherapeutics plc (NASDAQ: BRNS) within the context of a financial data platform. It shows the company's stock market information and indicates that the market is currently closed with no trades. The article

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 15:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Barinthus Biotherapeutics plc – NASDAQ:BRNS

This article provides the "Price to earnings forward" financial data for Barinthus Biotherapeutics plc (NASDAQ:BRNS). It appears to be a direct data output from a financial platform, showing the value and change percentages for this specific metric, though the values themselves a

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Barinthus Biotherapeutics plc Sponsored ADR – DUS:2AB

This page from TradingView provides financial information for Barinthus Biotherapeutics plc Sponsored ADR (DUS:2AB), specifically focusing on its Enterprise Value to EBITDA forward metric. The platform indicates that the market is currently closed for this stock, with no trades r

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:40
Source
TradingView
TradingView Direct company coverage

BRNS Forecast — Price Target — Prediction for 2027

This article provides a brief forecast for Barinthus Biotherapeutics plc (BRNS), indicating a consensus 1-year price target of $7.00 from one analyst. It also touches upon analyst ratings, EPS, and revenue metrics, noting that these are not investment advice.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

2AB Forecast — Price Target — Prediction for 2027

This article provides a price target for Barinthus Biotherapeutics plc Sponsored ADR (2AB) on the Frankfurt Stock Exchange, estimating it at 6.05. It notes that one analyst provided a one-year price forecast. The article also includes sections for analyst ratings, EPS, and revenu

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 22:11
Source
TradingView
TradingKey Direct company coverage

Barinthus Biotherapeutics PLC (BRNS) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Barinthus Biotherapeutics PLC (BRNS), noting its current financial score of 6.82, which ranks it 201 out of 387 in the Biotechnology & Medical Research industry. While the company's financial status is robust, its operating eff

Tone
Neutral 50/100
Event
Market update
Published
20 Jun 2026 20:10
Source
TradingKey
TradingKey Direct company coverage

Barinthus Biotherapeutics PLC (BRNS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Barinthus Biotherapeutics PLC (BRNS), listing its major individual and institutional holders. It also breaks down shareholder types, including venture capital, investment advisors, and individual investors, and provides quarterly

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 14:17
Source
TradingKey
TradingKey Direct company coverage

Barinthus Biotherapeutics PLC

This article provides an overview of Barinthus Biotherapeutics PLC (BRNS), a company listed on Nasdaq, including its current stock price and market capitalization. It highlights that relevant revenue breakdown data for the company by business segment and region has not yet been d

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 04:09
Source
TradingKey
TradingKey Direct company coverage

Barinthus Biotherapeutics PLC (BRNS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Barinthus Biotherapeutics PLC's (BRNS) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split events. The page also presents current stock pric

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 00:09
Source
TradingKey
TradingKey Direct company coverage

Barinthus Biotherapeutics PLC (BRNS) Institutional Confidence

Barinthus Biotherapeutics PLC (BRNS) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. Institutional shareholding decreased by 10.63% quarter-over-quarter, with the latest proportion at 40.87%. James Sim

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 16:39
Source
TradingKey
TradingKey Direct company coverage

Barinthus Biotherapeutics PLC (BRNS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Barinthus Biotherapeutics PLC (BRNS) has an earnings forecast score of 8.00, placing it 163rd out of 388 in its industry. Analysts have set an average price target of $5.50 for BRNS, with a strong "Buy" trend based on the ratings of two analysts. The company's recent EPS was -$0.

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 12:40
Source
TradingKey
TradingKey Direct company coverage

Barinthus Biotherapeutics PLC (BRNS) Valuation: PE, PB & Fair Value Analysis

Barinthus Biotherapeutics PLC (BRNS) has a current valuation score of 8.28, ranking 156 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.54, which is significantly below its recent high and above its recent low. Key valuation metrics like

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 15:40
Source
TradingKey
Stock Titan Direct company coverage

[ARS] Barinthus Biotherapeutics plc. SEC Filing

This article announces an ARS SEC filing by Barinthus Biotherapeutics plc. (BRNS) on June 10, 2026. The filing is available as a PDF document through the SEC EDGAR system. The company's stock overview, market cap, and recent news and SEC filings are also provided.

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

Barinthus Biotherapeutics (BRNS) schedules 2026 AGM with 7 key votes

Barinthus Biotherapeutics (BRNS) has scheduled its 2026 Annual General Meeting for July 2, 2026, in London, where shareholders will vote on seven key proposals. These proposals include the re-election of two Class II directors, Karen T. Dawes and Anne M. Phillips, as well as the

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 21:09
Source
Stock Titan
Finviz Direct company coverage

BRNS - Barinthus Biotherapeutics Plc ADR Stock Price and Quote

This article provides a detailed stock quote and financial overview for Barinthus Biotherapeutics Plc (BRNS), including its last close price, key financial metrics, various performance indicators, and recent news and analyst actions. The company is a clinical-stage biopharmaceuti

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jun 2026 11:09
Source
Finviz
Investing.com South Africa Direct company coverage

Barinthus Biotherapeutics shareholders approve scheme of arrangement By Investing.com

Barinthus Biotherapeutics shareholders have overwhelmingly approved a scheme of arrangement and related implementation proposal at recent meetings. The company's American Depositary Shares are listed on the Nasdaq Global Market under the symbol BRNS, and despite current trading a

Tone
Positive 62/100
Event
Market update
Published
22 May 2026 06:09
Source
Investing.com South Africa
Investing.com UK Direct company coverage

Barinthus Biotherapeutics shareholders approve scheme of arrangement

Barinthus Biotherapeutics shareholders have overwhelmingly approved a scheme of arrangement and related implementation proposals at recent meetings. The company, trading at $0.69 with a market cap of $28 million, received 99.98% support from voting shareholders despite being sign

Tone
Positive 71/100
Event
Market update
Published
21 May 2026 12:10
Source
Investing.com UK
Stock Titan Direct company coverage

Barinthus Biotherapeutics (NASDAQ: BRNS) investors back scheme implementation

Barinthus Biotherapeutics' shareholders overwhelmingly approved a Scheme of Arrangement and related Scheme Implementation Proposal during recent court and general meetings. An impressive 99.98% of votes were cast in favor of the proposals at both meetings, ensuring a smooth path

Tone
Positive 70/100
Event
Market update
Published
21 May 2026 10:09
Source
Stock Titan
Business Wire Direct company coverage

Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS

Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between Barinthus Biotherapeutics plc (BRNS) and Clywedog Therapeutics, Inc. The law firm is examining whether the merger is fair to Barinthus shareholders, who will own only 34.33% of the combined company. KSF is

Tone
Neutral 50/100
Event
Deals and strategy
Published
11 May 2026 16:10
Source
Business Wire
TradingKey Direct company coverage

BRNS Stock Quote

This page provides a stock quote for Barinthus Biotherapeutics PLC (BRNS) on TradingKey. It shows the current price of 0.685 USD, a 2.24% increase, and a market cap of 27.97M, reflecting its performance as of May 11, 16:00 ET. The page also features an overview of the company, fi

Tone
Neutral 50/100
Event
Market update
Published
11 May 2026 14:10
Source
TradingKey
FinancialContent Direct company coverage

Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS

Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between Barinthus Biotherapeutics plc (BRNS) and Clywedog Therapeutics, Inc. The investigation aims to determine if the merger terms are fair to Barinthus shareholders, who will own only 34.33% of the combined comp

Tone
Negative 36/100
Event
Deals and strategy
Published
11 May 2026 12:08
Source
FinancialContent